根治性膀胱切除术后晚期复发具有独特的预后与管理考量
该研究基于2000至2014年间2315例因尿路上皮癌行根治性膀胱切除术的患者,其中617例复发,比较了术后3年内与3年后复发的基线特征及复发后管理。晚期复发患者T分期和淋巴结阳性率更低,复发后1年膀胱癌死亡率随复发时间延长而下降。局部巩固治疗在晚期复发中更常见,且在该亚组中早期复发者的癌症特异性生存显著更差。
要点
- 晚期复发(>3年)患者T分期更低、淋巴结受累更少。
- 复发后1年膀胱癌死亡率随复发时间延长而下降(6个月66%→2年50%→5年33%)。
- 局部巩固治疗(转移灶切除或放疗)在晚期复发中更常见(19% vs 3.6%,p<0.0001)。
核心结论
- 根治性膀胱切除术后晚期复发患者生存期较长,可据此个体化管理。
- 有充分理由研究转移灶切除在晚期复发管理中的作用。
研究设计与样本
- 单中心回顾性研究,纳入2000至2014年因尿路上皮癌行根治性膀胱切除术的2315例患者,其中617例复发。
- 复发定义为泌尿道外复发,比较术后3年内与3年后复发的基线特征及复发后管理。
- 幸存者复发后中位随访2.6年(IQR 0.95-4.5)。
主要发现
- 58例晚期复发患者共识T分期显著更低、淋巴结受累频率更低。
- 复发后1年平均膀胱癌死亡率:术后6个月复发者为66%,2年者为50%,5年者为33%。
- 复发后存活至少1年者,晚期复发患者复发后5年估计生存率为45%,早期复发者为21%。
- 局部巩固治疗(转移灶切除或放疗)在晚期复发中更常见(19% vs 3.6%,p<0.0001)。
- 在接受局部巩固治疗的亚组中,早期复发者的癌症特异性生存显著差于晚期复发者(p=0.02)。
关键数值与推荐
- 晚期复发定义为根治性膀胱切除术后超过3年的复发。
- 复发后1年膀胱癌死亡率从6个月复发者的66%降至2年者的50%和5年者的33%。
- 复发后存活≥1年者,晚期复发5年生存率45%,早期复发21%。
- 局部巩固治疗比例晚期复发19%,早期复发3.6%(p<0.0001)。
临床怎么用
- 对根治性膀胱切除术后晚期复发患者,可考虑更积极的局部巩固治疗(转移灶切除或放疗)。
- 晚期复发患者预后相对较好,管理策略可个体化。
局限性
- 单中心回顾性研究,晚期复发样本量较小(58例)。
- 幸存者复发后中位随访仅2.6年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Disease recurrence after radical cystectomy generally occurs within 2 years and has a poor prognosis. Less well defined are the outcomes in patients who experience a late recurrence (more than 3 years after radical cystectomy). We report our institutional experience with late recurrences and describe the relationships between time to recurrence, management strategies and survival. MATERIALS AND METHODS: The study cohort comprised 2,315 patients who underwent radical cystectomy for urothelial carcinoma at our center between 2000 and 2014, of whom 617 had a recurrence. Median followup for survivors was 2.6 years after recurrence (IQR 0.95-4.5). For the study we considered disease recurrence as recurrences outside the urinary tract. We compared baseline characteristics and post-recurrence management between those with recurrence 3 or less and more than 3 years after radical cystectomy. RESULTS: A total of 58 patients with late recurrence had significantly lower consensus T stage and lower frequency of nodal involvement. The average 1-year bladder cancer death rate from the time of recurrence declined from 66% to 50% to 33% for patients with recurrence times of 6 months, 2 years, and 5 years after radical cystectomy, respectively. For patients who survived at least 1 year after recurrence, the estimated survival at 5 years after recurrence was 45% for those with late recurrence and 21% for patients who had an early recurrence. Local consolidative therapy (metastasectomy or radiation) was more common in patients with late recurrence (19% vs 3.6%, p <0.0001). Cancer specific survival in early recurring cases was significantly worse than in late recurring cases in the subset receiving local consolidation (p=0.02). CONCLUSIONS: The prolonged lifespan of patients experiencing a late recurrence after radical cystectomy can be leveraged to individualize management. There is strong rationale for investigating the role of metastasectomy in the management of late recurrences.
引用
- Dason S, Cha EK, Falavolti C, et al. Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. J Urol. 2020. PMID: 32253982. doi:10.1097/JU.0000000000001028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。